Merck ROE 2010-2022 | MRK

Current and historical return on equity (ROE) values for Merck (MRK) over the last 10 years. Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested.
Merck ROE - Return on Equity Historical Data
Date TTM Net Income Shareholder's Equity Return on Equity
2022-06-30 $16.58B $43.32B 41.87%
2022-03-31 $14.18B $40.95B 38.21%
2021-12-31 $13.05B $38.26B 38.79%
2021-09-30 $7.20B $35.86B 23.65%
2021-06-30 $5.57B $33.39B 19.36%
2021-03-31 $7.03B $27.04B 25.68%
2020-12-31 $7.07B $25.40B 26.00%
2020-09-30 $11.52B $29.27B 42.15%
2020-06-30 $10.48B $27.74B 39.18%
2020-03-31 $10.15B $26.30B 37.95%
2019-12-31 $9.84B $26.00B 36.34%
2019-09-30 $9.31B $26.93B 34.11%
2019-06-30 $9.36B $27.74B 32.58%
2019-03-31 $8.40B $27.67B 28.00%
2018-12-31 $6.22B $26.88B 19.71%
2018-09-30 $3.35B $32.66B 10.00%
2018-06-30 $1.34B $32.77B 3.84%
2018-03-31 $1.58B $33.90B 4.31%
2017-12-31 $2.39B $34.57B 6.26%
2017-09-30 $2.85B $38.50B 7.18%
2017-06-30 $5.09B $39.71B 12.40%
2017-03-31 $4.35B $40.09B 10.36%
2016-12-31 $3.92B $40.31B 9.14%
2016-09-30 $5.49B $43.96B 12.47%
2016-06-30 $5.13B $43.45B 11.55%
2016-03-31 $4.61B $43.90B 10.20%
2015-12-31 $4.44B $44.77B 9.60%
2015-09-30 $10.78B $45.68B 22.82%
2015-06-30 $9.85B $46.64B 20.88%
2015-03-31 $11.17B $47.92B 23.44%
2014-12-31 $11.92B $48.79B 24.42%
2014-09-30 $5.39B $45.36B 10.84%
2014-06-30 $5.61B $48.52B 11.04%
2014-03-31 $4.52B $52.56B 8.81%
2013-12-31 $4.40B $52.33B 8.47%
2013-09-30 $4.53B $50.01B 8.58%
2013-06-30 $5.14B $50.11B 9.36%
2013-03-31 $6.02B $55.61B 10.61%
2012-12-31 $6.17B $55.46B 10.78%
2012-09-30 $6.76B $58.21B 11.75%
2012-06-30 $6.72B $57.67B 11.71%
2012-03-31 $6.95B $57.31B 12.10%
2011-12-31 $6.26B $56.94B 10.91%
2011-09-30 $4.22B $57.60B 7.36%
2011-06-30 $2.87B $57.92B 5.00%
2011-03-31 $1.60B $56.84B 2.80%
2010-12-31 $0.86B $56.81B 1.48%
2010-09-30 $7.84B $58.05B 13.20%
2010-06-30 $10.92B $57.67B 21.33%
2010-03-31 $11.73B $60.34B 27.60%
2009-12-31 $12.85B $61.49B 39.07%
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $218.318B $48.704B
Merck & Co. boasts more than six blockbuster drugs in its portfolio with PD-L1 inhibitor, Keytruda, approved for several types of cancer. Keytruda has played an instrumental role in driving Merck's steady revenue growth in the past few years. Well-known products in Merck's portfolio include Keytruda, Simponi , Januvia and Janumet, Bridion, Isentress, ProQuad, Gardasil, Pneumovax 23, RotaTeq and Belsomra. Merck made its biggest acquisition of Schering-Plough and sold off its Consumer Care business to Bayer. Other key acquisitions include Idenix Pharmaceuticals, Cubist Pharmaceuticals, Rigontec, ArQule and Acceleron Pharma. IMerck spun off products from its Women's Health unit, legacy drugs and biosimilar products into a new publicly traded company called Organon & Co.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $435.655B 16.59
Eli Lilly (LLY) United States $292.179B 37.05
AbbVie (ABBV) United States $249.673B 10.61
Pfizer (PFE) United States $245.989B 7.21
Novo Nordisk (NVO) Denmark $215.616B 28.44
Novartis AG (NVS) Switzerland $165.082B 12.17